Prevalence of Human Papillomavirus 16 and 18 Neutralizing Antibodies in Prenatal Women in British Columbia

ABSTRACT Human papillomavirus (HPV) type 16 and 18 neutralizing antibody (NAb) titers were measured in 1,020 prenatal women in British Columbia aged 15 to 39. HPV 16 and 18 NAbs were detected in 183/1,020 (17.9%) and 97/1,020 (9.5%), respectively, and 39 (3.8%) had NAbs to both types. Titers were similar across age strata.

Download Full-text

In Vitro Infection and Type-Restricted Antibody-Mediated Neutralization of Authentic Human Papillomavirus Type 16

Journal of Virology ◽

10.1128/jvi.72.2.959-964.1998 ◽

1998 ◽

Vol 72 (2) ◽

pp. 959-964 ◽

Cited By ~ 90

Author(s):

Wendy I. White ◽

Susan D. Wilson ◽

William Bonnez ◽

Robert C. Rose ◽

Scott Koenig ◽

...

Keyword(s):

Human Papillomavirus ◽

Neutralizing Antibodies ◽

Cultured Cells ◽

Severe Combined Immunodeficiency ◽

Neutralizing Antibody ◽

Neutralization Assay ◽

Model Systems ◽

Hpv 16 ◽

Human Papillomavirus Type 16

ABSTRACT Human papillomavirus type 16 (HPV-16) is strongly associated with the development of cervical cancer. Studies of model systems with animal papillomaviruses have demonstrated the importance of neutralizing antibodies in preventing papillomavirus-associated disease. The assessment of neutralizing antibody responses against HPV-16, previously hampered by the lack of a viral source, was enabled by the recent propagation of an HPV-16 stock in xenografted severe combined immunodeficiency (SCID) mice. HPV-16 infection of an immortalized human keratinocyte cell line was demonstrated by detection of an HPV-16-specific spliced mRNA amplified by reverse transcriptase PCR. Infection was blocked by preincubation of the virus with antiserum generated against HPV-16 virus-like particles (VLPs) composed of the major capsid protein, L1. To examine potential cross-neutralizing activity among the different genital HPV types, rabbit antisera to L1 VLPs corresponding to HPV-6, -11, -18, -31, -33, -35, -39, and -45 were assayed for the ability to block the HPV-16 infection of cultured cells. Antiserum raised against HPV-33 L1 VLPs was the only heterologous antiserum which inhibited HPV-16 infection. Thus, a neutralization assay for HPV-16 may help to characterize the components required to compose a broadly efficacious genital HPV vaccine.

Download Full-text

Measurement of the Humoral Immune Response following an Incident Human Papillomavirus Type 16 or 18 Infection in Young Women by a Pseudovirion-Based Neutralizing Antibody Assay

Clinical and Vaccine Immunology ◽

10.1128/cvi.00013-08 ◽

2008 ◽

Vol 15 (9) ◽

pp. 1387-1390 ◽

Cited By ~ 8

Author(s):

Jane Steele ◽

Stuart Collins ◽

Kaisheng Wen ◽

Gordon Ryan ◽

Christothea Constandinou-Williams ◽

...

Keyword(s):

Human Papillomavirus ◽

Young Women ◽

Neutralizing Antibodies ◽

Neutralizing Antibody ◽

Enzyme Linked Immunosorbent Assay ◽

Serological Response ◽

Antibody Assay ◽

Hpv 16 ◽

Hpv 18

ABSTRACT We have evaluated a neutralizing antibody assay which uses human papillomavirus (HPV) type 16 (HPV-16) and HPV-18 pseudovirions carrying a secretory alkaline phosphatase reporter gene and which can potentially measure functionally relevant HPV type-specific neutralizing antibodies. The reproducibility of the assay was excellent; for HPV-16, the intra- and interassay kappa values were 0.95 and 0.90, respectively; and for HPV-18, the corresponding values were 0.90 and 0.90. This assay was used to describe the kinetics of the neutralizing antibody response in a cohort of 42 young women who were recruited soon after first intercourse and who first tested positive for HPV-16 DNA or HPV-18 DNA, or both, during follow-up. Most women seroconverted following the first detection of type-specific HPV DNA and remained seropositive until the end of follow-up. Our findings are broadly consistent with those of two other cohort studies which have measured the serological response following an incident infection by using the technically simpler virus-like-particle-based enzyme-linked immunosorbent assay.

Download Full-text

Acquisition and Persistence of Human Papillomavirus 16 (HPV-16) and HPV-18 Among Men With High-HPV Viral Load Infections in a Circumcision Trial in Kisumu, Kenya

The Journal of Infectious Diseases ◽

10.1093/infdis/jiu535 ◽

2014 ◽

Vol 211 (5) ◽

pp. 811-820 ◽

Cited By ~ 12

Author(s):

Virginia Senkomago ◽

Danielle M. Backes ◽

Michael G. Hudgens ◽

Charles Poole ◽

Kawango Agot ◽

...

Keyword(s):

Human Papillomavirus ◽

Viral Load ◽

Hpv 16 ◽

Human Papillomavirus 16 ◽

Hpv Viral Load ◽

Hpv 18

Download Full-text

Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease

Journal of General Virology ◽

10.1099/vir.0.83458-0 ◽

2008 ◽

Vol 89 (4) ◽

pp. 910-914 ◽

Cited By ~ 10

Author(s):

Zizipho Z. A. Mbulawa ◽

Anna-Lise Williamson ◽

Debbie Stewart ◽

Jo-Ann S. Passmore ◽

Lynette Denny ◽

...

Keyword(s):

Human Papillomavirus ◽

Neutralizing Antibodies ◽

Antibody Responses ◽

Normal Cytology ◽

Hpv 16 ◽

Human Papillomavirus Type 16 ◽

Immunodeficiency Virus ◽

Cervical Disease ◽

Hpv Types

We investigated neutralizing antibodies to human papillomavirus type 16 (HPV-16) in serum and cervical washes from 84 women with normal cytology or cervical disease. Serum neutralizing antibodies were detected in 78 % of women infected at the cervix with HPV-16, compared with 35 % (P=0.002) of women infected with HPV-16-related types (α9 HPV types), 14 % (P<0.0001) of women infected with HPV-16 non-related types and none of HPV-uninfected women. A significant correlation between HPV-16 infection and serum HPV-16-neutralizing antibodies was observed (r s=0.97; P=0.032). Cervical neutralizing antibodies were detected in 38 % of women with HPV-16 infection and in 17 % of women infected with the HPV-16-related type HPV-31. Cervical neutralizing antibodies correlated with HPV-16 infection (r s=0.95; P=0.08), but not with cervical disease. Serum and cervical HPV-16 antibody responses were not affected significantly by human immunodeficiency virus type 1 infection. In conclusion, serum and cervical HPV-16-neutralizing antibodies were found to correlate with HPV-16 infection, but not with cervical disease.

Download Full-text

The human papillomavirus-16 (HPV-16) oncoprotein E7 conjugates with and mediates the role of the transforming growth factor-beta inducible early gene 1 (TIEG1) in apoptosis

The International Journal of Biochemistry & Cell Biology ◽

10.1016/j.biocel.2010.07.019 ◽

2010 ◽

Vol 42 (11) ◽

pp. 1831-1839 ◽

Cited By ~ 8

Author(s):

Hung-Shu Chang ◽

Ching-Hui Lin ◽

Chien-Hui Yang ◽

Yuh-Jin Liang ◽

Winston C.Y. Yu

Keyword(s):

Human Papillomavirus ◽

Growth Factor ◽

Transforming Growth Factor Beta ◽

Transforming Growth Factor ◽

Early Gene ◽

Hpv 16 ◽

Human Papillomavirus 16 ◽

Growth Factor Beta

Download Full-text

Development of Bead-based Immunoassay to Quantify Neutralizing Antibody for Human Papillomavirus 16 and 18

Molecular Biotechnology ◽

10.1007/s12033-012-9571-2 ◽

2012 ◽

Vol 54 (2) ◽

pp. 361-370 ◽

Cited By ~ 1

Author(s):

Hai-Bo Liu ◽

Pankaj Kumar Chaturvedi ◽

Gantumur Battogtokh ◽

Hyo Joo Bang ◽

In-Wook Kim ◽

...

Keyword(s):

Human Papillomavirus ◽

Neutralizing Antibody ◽

Human Papillomavirus 16

Download Full-text

Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

Clinical and Vaccine Immunology ◽

10.1128/cvi.00591-14 ◽

2015 ◽

Vol 22 (4) ◽

pp. 361-373 ◽

Cited By ~ 62

Author(s):

Dan Apter ◽

Cosette M. Wheeler ◽

Jorma Paavonen ◽

Xavier Castellsagué ◽

Suzanne M. Garland ◽

...

Keyword(s):

Human Papillomavirus ◽

Young Women ◽

Sexual Debut ◽

Vaccine Dose ◽

Hpv 16 ◽

Substantial Impact ◽

Hpv Dna ◽

Human Papillomavirus 16 ◽

Adjuvanted Vaccine ◽

Event Driven

ABSTRACTWe report final event-driven analysis data on the immunogenicity and efficacy of the human papillomavirus 16 and 18 ((HPV-16/18) AS04-adjuvanted vaccine in young women aged 15 to 25 years from the PApilloma TRIal against Cancer In young Adults (PATRICIA). The total vaccinated cohort (TVC) included all randomized participants who received at least one vaccine dose (vaccine,n= 9,319; control,n= 9,325) at months 0, 1, and/or 6. The TVC-naive (vaccine,n= 5,822; control,n= 5,819) had no evidence of high-risk HPV infection at baseline, approximating adolescent girls targeted by most HPV vaccination programs. Mean follow-up was approximately 39 months after the first vaccine dose in each cohort. At baseline, 26% of women in the TVC had evidence of past and/or current HPV-16/18 infection. HPV-16 and HPV-18 antibody titers postvaccination tended to be higher among 15- to 17-year-olds than among 18- to 25-year-olds. In the TVC, vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 1 or greater (CIN1+), CIN2+, and CIN3+ associated with HPV-16/18 was 55.5% (96.1% confidence interval [CI], 43.2, 65.3), 52.8% (37.5, 64.7), and 33.6% (−1.1, 56.9). VE against CIN1+, CIN2+, and CIN3+ irrespective of HPV DNA was 21.7% (10.7, 31.4), 30.4% (16.4, 42.1), and 33.4% (9.1, 51.5) and was consistently significant only in 15- to 17-year-old women (27.4% [10.8, 40.9], 41.8% [22.3, 56.7], and 55.8% [19.2, 76.9]). In the TVC-naive, VE against CIN1+, CIN2+, and CIN3+ associated with HPV-16/18 was 96.5% (89.0, 99.4), 98.4% (90.4, 100), and 100% (64.7, 100), and irrespective of HPV DNA it was 50.1% (35.9, 61.4), 70.2% (54.7, 80.9), and 87.0% (54.9, 97.7). VE against 12-month persistent infection with HPV-16/18 was 89.9% (84.0, 94.0), and that against HPV-31/33/45/51 was 49.0% (34.7, 60.3). In conclusion, vaccinating adolescents before sexual debut has a substantial impact on the overall incidence of high-grade cervical abnormalities, and catch-up vaccination up to 18 years of age is most likely effective. (This study has been registered atClinicalTrials.govunder registration no. NCT001226810.)

Download Full-text

Serologic response to human papillomavirus 16 among Australian women with high-grade cervical intraepithelial neoplasia

International Journal of Gynecological Cancer ◽

10.1136/ijgc-00009577-200605000-00013 ◽

2006 ◽

Vol 16 (3) ◽

pp. 1032-1035

Author(s):

S. N. Tabrizi ◽

I. H. Frazer ◽

S. M. Garland

Keyword(s):

Human Papillomavirus ◽

Cervical Intraepithelial Neoplasia ◽

Intraepithelial Neoplasia ◽

High Grade ◽

Hpv 16 ◽

Hpv Dna ◽

Human Papillomavirus 16 ◽

Serologic Response ◽

Poor Predictor ◽

Hpv Types

This study evaluated the detection of human papillomavirus (HPV) 16 antibody in HPV 16–associated cervical intraepithelial neoplasia (CIN) in Australian women. Seroreactivity to HPV 16 L1 virus–like particles was assessed in patients with CIN 2 (n = 169) and CIN 3 (n = 229) lesions previously tested for the presence of HPV DNA. Seropositivity was significantly commoner in women with HPV 16 DNA–positive lesions (98/184) than in women with no HPV DNA in the lesion (15/47) or with HPV of types other than 16 in the lesion (43/167) (P = 0.0004). In addition, seropositivity was observed in 33% (55/169) of women with CIN 2 and 46% (106/229) of women with CIN 3, in keeping with the lower fraction of CIN 2 (57/169) than CIN 3 (127/229) biopsies positive for HPV 16 DNA. HPV 16 seropositivity is most common in women with HPV 16–associated CIN, but many patients with HPV-associated CIN 3 are seronegative, and HPV 16 seropositivity is common in women with CIN associated with other HPV types. Overall, HPV 16 serology is a poor predictor of presence of HPV 16–associated CIN 3 in patient population studied.

Download Full-text